The frequency and clinical impact of HER2 alterations in lung adenocarcinoma

scientific article

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2017PLoSO..1271280K
P356DOI10.1371/JOURNAL.PONE.0171280
P932PMC publication ID5287480
P698PubMed publication ID28146588

P50authorHyo Sup ShimQ59690264
P2093author name stringEun Kyung Kim
Chang Young Lee
Kyung A Kim
P2860cites workThe role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.Q33770932
Lung cancer: intragenic ERBB2 kinase mutations in tumoursQ34354426
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.Q34536780
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysisQ36072192
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationQ36322762
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.Q36423790
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomasQ36644476
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Q37398636
Targeting HER2 in the treatment of non-small cell lung cancerQ38324334
Effect of HER2/neu expression on survival in non-small-cell lung cancerQ47289478
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.Q50775865
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.Q27824805
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trialQ27824810
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.Q27851719
Cancer statistics, 2015Q27860576
Untangling the ErbB signalling networkQ27860884
Comprehensive molecular profiling of lung adenocarcinomaQ28244995
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesQ28289431
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.Q33359693
Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.Q51544956
HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.Q52996871
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.Q53381227
Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.Q54313117
HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.Q54336136
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ57130157
HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistryQ79078748
HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptinQ79289949
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gainsQ82448154
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectadenocarcinomaQ356033
P304page(s)e0171280
P577publication date2017-02-01
P1433published inPLOS OneQ564954
P1476titleThe frequency and clinical impact of HER2 alterations in lung adenocarcinoma
P478volume12

Reverse relations

cites work (P2860)
Q55396331Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.
Q90091776Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer
Q92859970Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
Q47261688Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Q90513170Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
Q55123690Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer.
Q54962247Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Q64084185The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
Q59813207The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1
Q46915997Understanding and targeting resistance mechanisms in NSCLC.

Search more.